Liver News and Research

RSS

Texas Children's Heart Center opens Center for Preventive Cardiology

Texas Children's Heart Center is proud to announce the opening of the Center for Preventive Cardiology, which is designed to medically manage the risk factors of acquired heart disease in children. The center is the only one of its kind in Texas that offers multidisciplinary, specialized care for children with these risk factors or who have a strong family history of cardiac disease, elevated cholesterol, high blood pressure or the diagnosis of Kawasaki disease.

13 Dec 2013

Study: Antisense drugs show activity in wide range of tissues and organs

Antisense therapeutics, a class of drugs comprised of short nucleic acid sequences, can target a dysfunctional gene and silence its activity. A new study has shown that antisense drugs delivered systemically show activity in a wide range of tissues and organs, supporting their broad therapeutic potential in many disease indications, as described in an article in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

13 Dec 2013

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures - including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center.

13 Dec 2013

Scientists bring stem cell science directly to patients

Scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research are bringing stem cell science funded by the California Institute of Regenerative Medicine (CIRM), the state stem cell agency, directly to patients in two exciting new clinical trials scheduled to begin in early 2014.

13 Dec 2013

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to researchers at Washington University School of Medicine in St. Louis.

13 Dec 2013

Researchers discover easy-to-use method for bonding gels and biological tissues

Researchers have discovered an efficient and easy-to-use method for bonding together gels and biological tissues. A team headed by Ludwik Leibler, involving researchers from the Laboratoire Matière Molle et Chimie (CNRS/ESPCI ParisTech) and the Laboratoire Physico-Chimie des Polymères et Milieux Dispersés (CNRS/ UPMC/ESPCI ParisTech), has succeeded in obtaining very strong adhesion between two gels by spreading on their surface a solution containing nanoparticles.

12 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013

Mitochondrial enzyme SIRT5 regulates proteins involved in metabolism

The Sirtuin family of protein deacylases has received considerable attention in recent years due to its links to longevity, diabetes, cancer, and metabolic regulation.

12 Dec 2013

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

HCV antiviral therapy also improves diabetes outcomes

Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus improves kidney and cardiovascular outcomes for patients with diabetes. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that incidences of kidney disease, stroke, and heart attack were lower in patients treated with pegylated interferon and ribavirin compared to HCV patients not treated with antivirals or diabetic patients not infected with the virus.

12 Dec 2013

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial.

11 Dec 2013

Sites selected by early human ancestors were abundant in nutrient-rich food, shows research

Research led by the University of Southampton has found that early humans were driven by a need for nutrient-rich food to select 'special places' in northern Europe as their main habitat.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology.

10 Dec 2013

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Michigan State University researchers have uncovered a genetic deficiency in males that can trigger the development of one of the most common types of liver cancer and forms of diabetes.

9 Dec 2013

Revised Clinical Practice Guidelines on management of HCV published by EASL

The European Association for the Study of the Liver today publishes their revised Clinical Practice Guidelines (CPGs) on the management of hepatitis C virus infection. The EASL guidelines, which supersede the previous version published in 2011, are designed to help physicians and other healthcare providers optimise their management of patients with acute and chronic HCV.

9 Dec 2013

Skin is capable of communicating with liver, say researchers

Researchers from the University of Southern Denmark have discovered that the skin is capable of communicating with the liver. The discovery has surprised the scientists, and they say that it may help our understanding of how skin diseases can affect the rest of the body.

9 Dec 2013

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

Diabetes was associated with an increased risk for developing a type of liver cancer called hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Liver News and Research

Texas Children's Heart Center opens Center for Preventive Cardiology

Study: Antisense drugs show activity in wide range of tissues and organs

Over-use of staging procedures more prevalent in younger, early-stage breast cancer patients

Scientists bring stem cell science directly to patients

Drugs to treat type 2 diabetes may have different effects on hearts of men and women

Researchers discover easy-to-use method for bonding gels and biological tissues

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

Mitochondrial enzyme SIRT5 regulates proteins involved in metabolism

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Emergent BioSolutions enters into definitive agreement to acquire Cangene

HCV antiviral therapy also improves diabetes outcomes

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Sites selected by early human ancestors were abundant in nutrient-rich food, shows research

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Revised Clinical Practice Guidelines on management of HCV published by EASL

Skin is capable of communicating with liver, say researchers

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News